A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas | Scientific Reports
Enhanced Copper–Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme | ACS Applied Materials & Interfaces
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors | SpringerLink
PDF) Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
Metronomic treatment in immunocompetent preclinical glioblastoma | SeRMN – NMR Service at UAB
Enhanced Copper–Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme | ACS Applied Materials & Interfaces
Biomedicines | Free Full-Text | Considering the Experimental Use of Temozolomide in Glioblastoma Research
Preliminary results from the NCT02770378 proof-of-concept clinical trial assessing the safety of the Coordinated Undermining of
Treatment of Glioblastoma | JCO Oncology Practice
PDF) Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions | PLOS ONE
Frontiers | Temozolomide – Just a Radiosensitizer?
PDF) Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours | A. Koumarianou - Academia.edu
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas | BMC Cancer | Full Text
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens | Journal of Pharmacology and Experimental Therapeutics
PDF) Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
PDF) Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images - Wu - 2020 - NMR in Biomedicine - Wiley Online Library
Cancers | Free Full-Text | Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells
Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation
JCM | Free Full-Text | Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Metronomic and Conventional Temozolomide Dosing Regimens | Journal of Pharmacology and Experimental Therapeutics
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells
Phase II trials of metronomic temozolomide schedules for glioblastoma | Download Table
Metronomic treatment of temozolomide increases anti-angiogenicity accompanied by down-regulated O6-methylguanine-DNA methyltransferase expression in endothelial cells
Cancers | Free Full-Text | Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells
